Table 1 Relationship between clinical characteristics and PD-L1 and PD-1 expression in intrahepatic cholangiocarcinoma
n | PD-L1 expression | PD-1 expression | |||||
|---|---|---|---|---|---|---|---|
Cancerous cell (+) | p value | Stromal cells (+) | p value | Lymphocyte (+) | p value | ||
Total number | 69 | 8 (11.6%) | 35 (50.7%) | 21 (30.4%) | |||
Age, years; median (range) | 60 (34–81) | 63 (46–79) | 0.499 | 63 (43–81) | 0.025 | 60 (50–76) | 0.984 |
Gender | 0.266 | 0.264 | 0.006 | ||||
Male | 40 | 3 (7.5%) | 18 (45%) | 7 (17.5%) | |||
Female | 29 | 5 (17.2%) | 17 (58.6%) | 14 (48.3%) | |||
HBV infection | 28 | 0.337 | 0.555 | 0.781 | |||
HBsAg, positive | 5 (17.9%) | 13 (46.4%) | 8 (28.6) | ||||
HBsAg, negative | 3 (7.3%) | 22 (53.7%) | 13 (31.7%) | ||||
CA19-9 > 39.9U/ml | 38 | 0.494 | 0.726 | 0.177 | |||
CA19-9, positive | 3 (7.9%) | 20 (52.6%) | 9 (23.7%) | ||||
CA19-9, negative | 5 (16.1%) | 15 (48.4%) | 13 (41.9%) | ||||
TB > 20.5umol/L | 13 | 1.0 | 0.803 | 0.33 | |||
TB, positive | 2 (15.4%) | 7 (53.8%) | 2 (15.4%) | ||||
TB, negative | 6 (10.7%) | 28 (50%) | 19 (33.9%) | ||||
DB > 6.8umol/L | 10 | 0.865 | 0.187 | 0.974 | |||
DB, positive | 1 (10%) | 7 (70%) | 3 (30%) | ||||
DB, negative | 7 (11.9%) | 28 (47.5%) | 18 (30.5%) | ||||
ALT > 40U/L | 16 | 0.644 | 0.184 | 0.916 | |||
ALT, positive | 3 (18.8%) | 11 (68.8%) | 5 (31.3%) | ||||
ALT, negative | 5 (9.4%) | 24 (45.3%) | 16 (30.2%) | ||||
AST > 40U/L | 18 | 0.724 | 0.305 | 0.776 | |||
AST, positive | 3 (16.7%) | 11 (61.1%) | 5 (27.8%) | ||||
AST, negative | 5 (9.8%) | 24 (47.1%) | 16 (31.4%) | ||||
γ-GT > 35U/L | 48 | 0.957 | 0.056 | 0.824 | |||
γ-GT, positive | 5 (10.4%) | 28 (58.3%) | 15 (31.3%) | ||||
γ-GT, negative | 3 (14.3%) | 7 (33.3%) | 6 (28.6%) | ||||